Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode
This Biotech's Stock Could Double If Its Treatment for Major Depressive Disorder Succeeds, Says Mizuho
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $30
Neumora Therapeutics, Inc.: Strategic Advancements and Unique Efficacy in MDD Trials Drive Buy Rating
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $23